Trials / Completed
CompletedNCT02985398
An Open Label Trial of ALD403 (Eptinezumab) in Chronic Migraine
An Open Label Phase 3 Trial to Evaluate the Safety of ALD403 Administered Intravenously in Patients With Chronic Migraines
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 128 (actual)
- Sponsor
- Alder Biopharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
An evaluation of long term safety of repeat ALD403 doses in Chronic Migraine
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ALD403 (Eptinezumab) |
Timeline
- Start date
- 2016-12-01
- Primary completion
- 2018-04-01
- Completion
- 2019-03-01
- First posted
- 2016-12-07
- Last updated
- 2020-04-21
- Results posted
- 2020-04-21
Locations
20 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02985398. Inclusion in this directory is not an endorsement.